Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar belakang: Morbiditas akibat duktus arteriosus paten (DAP) pada neonatus cukup bulan (NCB) cukup tinggi. Peran prostaglandin E2 (PGE2), trombosit (immature platelet fraction, IPF), dan vascular endothelial growth factor (VEGF) pada penutupan DA secara fungsional dan anatomis pada NCB belum banyak diteliti. Patofisiologi terjadinya DAP dapat memengaruhi tata laksana farmakologi dini yang belum terstandardisasi pada NCB. Penggunaan obat antiinflamasi nonsteroid seperti ibuprofen dimungkinkan dapat menghambat jalur sintesis prostaglandin dengan efek samping minimal.Tujuan: Mengkaji peran prostaglandin E2, VEGF, IPF, dan efek pemberian ibuprofen oral dalam proses penutupan DA pada NCB.Metode: Penelitian dilakukan di rumah sakit (RS) Sanglah Denpasar, RS Prima Medika Denpasar, dan RS Umum Daerah Wangaya Denpasar, dalam periode Maret sampai Agustus 2015. Penelitian terdiri dari 2 desain, pertama desain potong lintang pada pasien dengan DAP dan tanpa DAP secara consecutive sampling dan desain kedua uji klinis acak terkontrol ganda pada pasien DAP usia ≥ 48 jam. Pasien dengan DAP kemudian dimasukkan dalam uji klinis, dilakukan randomisasi untuk diberikan perlakuan ibuprofen oral dosis hari pertama 10 mg/kg, hari kedua dan ketiga 5 mg/kg atau plasebo. Pemantauan hemodinamik dan efek samping obat dilakukan selama pemberian perlakuan. Pemeriksaan ekokardiografi, PGE2, VEGF, IPF, dan kreatinin dilakukan pada hari pertama dan keempat pascapemberian perlakuan.Hasil: Terdapat 64 subjek yang diteliti pada desain pertama dan 32 subjek pada desain kedua. Rerata kadar PGE2 lebih tinggi pada kelompok dengan DAP dibanding tanpa DAP, sedangkan rerata kadar VEGF dan IPF tidak berbeda. Ibuprofen oral tidak terbukti menurunkan diameter DA pascaperlakuan, tidak terdapat perbedaan rerata diameter pada kedua kelompok. Terdapat hubungan positif sedang terhadap perubahan kadar PGE2 dengan perubahan diameter DAP pascaperlakuan. Tidak terdapat perubahan hemodinamik atau efek samping akibat pemberian ibuprofen oral atau plasebo pada NCB dengan DAP.Simpulan: Tingginya kadar PGE2 terbukti berperan dalam patensi DA pada NCB. Ibuprofen oral dosis 10 - 5 - 5 mg/kgBB tidak mengecilkan diameter DAP.

---

Background: Serious morbidity impact due to patent ductus arteriosus (PDA) in full-term neonates remains high. The functional role of prostaglandin E2 (PGE2), platelet (immature platelet fraction, IPF), and vascular endothelial growth factor (VEGF) has not been studied in the closure mechanism of ductus arteriosus (DA). Understanding of pathophysiology of PDA may influence early pharmacological treatments, which have not been standardized in full-term neonates. The use of non-steroidal anti-inflammatory drugs such as ibuprofen can be beneficial as a pharmacological agent in enhancing the closure of PDA with minimal adverse effects.

Objectives: To evaluate the role of prostaglandin E2, VEGF, IPF, and the effect of oral ibuprofen in the process of DA closure in full-term neonates.

Methods: This study was conducted in Sanglah General Hospital, Prima Medika Hospital, and Wangaya Hospital Denpasar. The study consisted of two designs, the first was cross-sectional design in subjects with and without PDA using consecutive sampling and the second was double blind randomized controlled trial in full-term infant aged ≥ 48 hours. Subjects with PDA were randomized to oral ibuprofen and placebo administration, in which ibuprofen was given consecutively 10 - 5 - 5 mg/kg. All subjects underwent echocardiography, PGE2, VEGF, and IPF assays. Hemodynamics monitoring was evaluated during trial and adverse effect due to ibuprofen was recorded by measuring urine volume and plasma creatinine level.

Results: From March to August 2015, there were 64 subjects recruited for the first design and 32 subjects in the second design. The mean level of PGE2 was higher significantly in the group with PDA than non PDA group, while the mean levels of VEGF and IPF showed no difference. In the second design, oral ibuprofen showed no effect in reducing DA diameter after treatment. There were no differences in mean diameter of DA in both groups before and after treatments. There was moderate positive relationship between levels of PGE2 and the change of PDA diameter. There were neither hemodynamic changes nor adverse effect due to the administration of oral ibuprofen or placebo.

Conclusions: A high level of PGE2 appears to play a pivotal role in DA patency of full-term neonates. Administration of oral ibuprofen in 10 - 5 - 5 mg/kg schedule could not induce PDA closure in full-term neonates."

"Latar belakang: Duktus Arteriosus Persisten (DAP) adalah penyakit jantung bawaan yang paling umum terjadi pada bayi prematur. Penutupan DA spontan pada bayi prematur berhubungan langsung dengan maturitas lumen duktus dan sensitivitas DA terhadap kadar prostaglandin E2 (PGE2). Tujuan: Untuk mengetahui korelasi antara kadar prostaglandin E2 (PGE2) dengan ukuran duktus arteriosus persisten (DAP) pada bayi prematur. Metode: Penelitian observasional dengan metode pengukuran berulang atau repeatedmeasure pada bayi yang terdeteksi DAP pada hari ke 2-3 di Rumah Sakit Cipto Mangunkusumo dan Rumah Sakit Fatmawati, Jakarta, dari bulan April-Mei 2014. Diagnosis DAP menggunakan ekokardiografi 2-D dan analisis kuantitatif kadar PGE2 menggunakan sistim immunoassay ELISA. Korelasi antara kadar PGE2 dengan diameter DA secara statistik dievaluasi menggunakan uji Korelasi Pearson. Hasilnya: Tiga puluh tiga bayi prematur {(UG rerata 31 (28-32) minggu, BL rerata 1360 (1000-1500) gram)} yang terdaftar pada penelitian ini. Hampir dua pertiga dari pasien adalah laki-laki. Hampir semua (30 dari 33) subyek mengalami penutupan spontan DA sebelum usia 10 hari. Rerata diameter DA adalah 2,9 (SD 0.5) mm dengan kecepatan maksimum aliran transduktal (DVmax) adalah 0,2 (SD 0,06) cm/detik dan rasio LA/Ao 1,5 (SD 0,2). Masing-masing rerata kadar PGE2 serum pada usia 2-3, 5-7, dan setelah 10 hari adalah 5238,6 (SD 1.225,2), 4178,2 (SD 1.534,5), dan 915,2, (SD 151,6) pg ml. Pada hari ke 2-3 kadar PGE2 serum berkorelasi dengan diameter DA (r = 0,667, p <0,001), tetapi tidak pada hari 5-7 (r = 0.292, p = 0,105) atau hari ke-10 (r = 0.041, p = 0,941). Kesimpulan: Ada korelasi positip yang kuat antara kadar PGE2 dengan diameter DA bayi prematur pada usia 2-3 hari, namun tidak ada korelasi yang bermakna antara kadar PGE2 dengan menetapnya DAP.

---

Background: Persistent ductus arteriosus (PDA) is a congenital heart disease most commonly occuring in premature infants. Spontaneous DA closure in premature infants has been suggested to be associated with the maturity of duct lumen and the sensitivity of DA to prostaglandin E2 (PGE2).

Objectives: To determine the correlation between the serum levels of prostaglandin E2 (PGE2) to the size of a persistent ductus arteriosus (PDA) in premature infants.

Methods: Observational study using repeated measures on premature infants with PDA detected at day 2-3 in Cipto Mangunkusumo Hospital and Fatmawati Hospital, Jakarta, from April-May 2014. Diagnosis of PDA using a 2-D echocardiography and the quantitative analysis of PGE2 levels using immunoassay ELISA system. The correlation between PGE2 level with DA diameter were statistically evaluated using the Pearson Correlation test.

Results: Thirty-three premature infants (median gestational age 31 (28-32) weeks of gestational age, median birth weight 1360 (1000-1500) grams) were enrolled. Almost two thirds of patients were male. Almost all (30 of 33) subjects had spontaneous closure of DA before the age of 10 days. Mean DA diameter was 2.9 (SD 0.5) mm with maximum flow velocity of 0.2 (SD 0.06) cm/sec and LA/Ao of 1.5 (SD 0.2). Mean levels of PGE2 at the age of 2-3, 5-7, and after 10 days were 5238.6 (SD 1225.2), 4178.2 (SD 1534.5), and 915.2 (SD 151.6) pg/ml, respectively. The level of PGE2 level at day 2-3 was correlated with DA diameter (r = 0.667, p < 0.001), but not at day 5-7 (r = 0.292, p = 0.105) or day 10 (r = 0.041, p = 0.941).

Conclusion: There is a quite strong correlation positive between the levels of PGE2 in DA diameter in preterm infants at 2-3 days of age, although the correlation between levels of PGE2 by the persistence of PDA was not significant."

"Latar belakang: Kanker serviks merupakan salah satu kanker yang paling banyak ditemui dengan angka kematian yang tinggi di seluruh dunia. Vascular Endothelial Growth Factor (VEGF) merupakan salah satu biomarker yang berfungsi sebagai faktor prognosis pada kanker serviks. Data ekspresinya terkait berbagai karakteristik kanker serviks yang ditemui pada hasil pemeriksaan Ultrasonografi (USG) dan Magnetic Resonance Imaging (MRI) pada pasien kanker serviks di Indonesia masih terbatas.Tujuan: Untuk mengetahui hubungan antara tingkat ekspresi VEGF, pemeriksaan USG, dan pemeriksaan MRI pada pasien kanker serviks.Metode: Studi diagnostik dengan metode cross-sectional dilakukan pada pasien kanker serviks yang datang ke RSUPN Cipto Mangunkusumo pada bulan September 2021 hingga Agustus 2022. Pasien yang didiagnosis kanker serviks yang belum mendapatkan terapi apapun dilakukan biopsi serviks dan pemeriksaan USG dan MRI. Pasien yang tidak dilakukan pemeriksaan USG dan MRI serta biopsi dikeluarkan dari penelitian. Pemeriksaan VEGF dilakukan pada jaringan serviks dan diinterpretasikan menggunakan H-score. Sensitivitas dan spesifisitas pemeriksaan VEGF dan USG dibandingkan dengan hasil MRI.Hasil: Terdapat 65 subjek yang diikutsertakan dalam penelitian (10 subjek stadium awal dan 55 subjek stadium lanjut). Tidak ada perbedaan ekspresi VEGF di antara pasien kanker serviks dihubungkan dengan stadium, tipe histologi, atau ukuran tumor yang berbeda. Ada interreliabilitas minimum antara pemeriksaan VEGF dan MRI. Ada interreliabilitas yang baik antara pemeriksaan USG dan MRI untuk menentukan stadium kanker, invasi parametrium, invasi kelenjar getah bening dan invasi mukosa vesika urinaria dan rektumKesimpulan: Tidak terdapat perbedaan ekspresi VEGF pada pasien kanker serviks dengan karakteristik yang berbeda. Hasil pemeriksaan USG dan MRI sebanding dalam menentukan stadium klinis pada pasien kanker serviks.

---

Background: Cervical cancer is one of the most common cancers with a high mortality rate worldwide. Vascular Endothelial Growth Factor (VEGF) is a biomarker that functions as a prognostic factor in cervical cancer. Expression data related to various characteristics of cervical cancer found on the results of Ultrasonography (US) and Magnetic Resonance Imaging (MRI) examinations in cervical cancer patients in Indonesia are still limited.

Purpose: To determine the relationship between VEGF expression levels, ultrasound examination and MRI examination in cervical cancer patients.

Methods: A diagnostic study using the cross-sectional method was conducted on cervical cancer patients who came to Cipto Mangunkusumo General Hospital from September 2021 to August 2022. Patients diagnosed with cervical cancer who had not received any therapy had cervical biopsies and ultrasound and MRI examinations. Patients who did not undergo ultrasound and MRI examinations and biopsies were excluded from the study. VEGF examination was performed on cervical tissue and interpreted using the H-score. The sensitivity and specificity of VEGF and ultrasound examinations were compared with MRI results.

Results: There were 65 subjects enrolled in the study (10 early-stage subjects and 55 advanced-stage subjects). There were no differences in VEGF expression among cervical cancer patients associated with different stages, histological types, or tumor sizes. There is minimal interreliability between VEGF and MRI examinations. There is good interreliability between ultrasound and MRI examinations for determining the stage of cancer, parametrial invasion, lymph node invasion and mucosal invasion of the bladder and rectum.

Conclusions: There are no differences in VEGF expression in cervical cancer patients with different characteristics. The results of ultrasound and MRI examinations are comparable in determining clinical staging in cervical cancer patients."

"Tujuan: Membandingkan kadar vascular endothelial growth factor VEGF dan placental growth factor PlGF plasma dan vitreus pada tikus diabetes dengan kontrol gula darah GD buruk, dengan perbaikan kontrol gula darah, dan tikus nondiabetes, dan melihat pengaruh perbaikan kontrol gula darah terhadap kadar VEGF dan PlGF. Metode: Penelitian ini merupakan uji eksperimental pada hewan coba tikus strain Sprague Dawley. Sebanyak 18 ekor tikus disertakan dalam penelitian dan secara acak dibagi ke dalam kelompok perlakuan n=14 dan kontrol n=4 . Kelompok perlakuan diberikan injeksi Streptozotocin untuk menginduksi diabetes. Tikus dengan kadar GD 72 jam pasca induksi lebih dari 300 mg/dL didiagnosis diabetes. Kadar GD diperiksa secara berkala pada seluruh subyek. Setelah 4 mingu, kelompok perlakuan dibagi ke dalam kelompok I untuk terminasi dan kelompok II untuk perbaikan kontrol GD dengan injeksi insulin selama 4 minggu berikutnya, begitu pula dengan kelompok kontrol. Saat terminasi, sampel plasma darah dan vitreus diambil untuk analisis kadar VEGF dan PlGF melalui pemeriksaan enzyme-linked immunosorbent assay ELISA. Hasil: Sebanyak 17 ekor tikus bertahan hidup hingga akhir penelitian dengan 1 ekor tikus mati dari kelompok perlakuan. Kadar GD kelompok perlakuan II menurun drastis dan mencapai normoglikemia. Pemeriksaan ELISA bulan pertama menunjukkan kadar VEGF vitreus kelompok perlakuan I cenderung lebih tinggi dibandingkan kontrol I, yakni 196,36 65,24 pg/dL dan 123,64 44,99 pg/dL p=0,20 . Pemeriksaan ELISA bulan kedua menunjukkan kadar PlGF vitreus kelompok perlakuan II lebih tinggi dibandingkan kontrol II, yakni 59,04 2,48 dan 51,93 3,15 p=0,01. Kadar VEGF vitreus dan plasma kelompok perlakuan I dan II tidak berbeda bermakna, sedangkan kadar PlGF vitreus dan plasma lebih tinggi pada bulan kedua. Kesimpulan: Kadar VEGF dan PlGF vitreus mengalami peningkatan pada kelompok tikus diabetes dibandingkan nondiabetes, dan perbaikan kontrol gula darah selama 1 bulan belum dapat menurunkan kadar VEGF dan PlGF.

---

Aim: To compare plasma and vitreous level of vascular endothelial growth factor VEGF and placental growth factor PlGF in diabetic rats with poor blood glucose BG control, reconstitution of good BG control, and nondiabetic rats, and to investigate the effect of reconstitution of good BG control to VEGF and PlGF plasma and vitreous level.

Methods: This is an experimental study using Sprague Dawley rats. Eighteen rats were divided into intervention group n 14 and control group n 4. Intervention group were given Streptozotocin STZ injection to induce diabetes. Rats with BG level more than 300 mg dL at 72 hours after injection were considered diabetes and successful models. BG levels were monitored periodically in all subjects. After 4 weeks, intervention group was randomly divided into group I for termination and group II for reconstitution of good BG control with insulin for following 4 weeks, and so was the control group. Plasma and vitreous samples were taken. VEGF and PlGF levels were detected with enzyme linked immunosorbent assay ELISA.

Results: Seventeen rats survived and one rat died in intervention group. BG level of intervention group II decreased dramatically to normoglycemia. ELISA at month 1 showed that VEGF vitreous level tend to be higher in intervention group I compared to control I, 196.36 65.24 pg dL and 123.64 44.99, respectively p 0.20. ELISA at month 2 showed that PlGF vitreous level of intervention group I were significantly higher compared to control I, 59.04 2.48 and 51.93 3.15, respectively p 0.01. Vitreous and plasma VEGF of intervention group I and II were not different, while vitreous and plasma PlGF were significantly higher in group II.

Conclusions: Vitreous levels of VEGF and PlGF were increased in diabetic rats compared to nondiabetic, and reconstitution of good BG control for 1 month were unable to reduce VEGF and PlGF levels. "

"Latar Belakang: ECP mampu menurunkan frekuensi angina, meningkatkan kualitas hidup, serta memperbaiki exercise–induced ischemia time. Manfaat tersebut dapat bertahan beberapa tahun setelah ECP. Mekanisme manfaat jangka panjang ECP tersebut telah dibuktikan akibat adanya angiogenesis yang diduga diperankan VEGF-A, VEGFR-2, dan miR-92a.Tujuan: Mengetahui efek ECP terhadap VEGF-A dan VEGFR-2, serta hubungannya dengan miR-92a pada pasien angina refrakter.Metode: Studi ini merupakan uji klinis acak tersamar ganda yang melibatkan 50 subjek dengan angina refrakter. Subjek dirandomisasi (1:1) ke dalam kelompok terapi ECP atau sham, yang masing-masing dilakukan selama 1 jam, hingga 35 kali. Kadar VEGF-A, VEGFR-2, dan miR-92a plasma diukur sebelum dan sesudah terapi menggunakan metode enzyme-linked immunosorbent assay (ELISA) untuk VEGF-A dan VEGFR-2, serta quantitative reverse transcription-polymerase chain reaction (qRT-PCR) untuk miR-92a. Keluaran klinis sekunder seperti derajat angina, kualitas hidup, 6-minutes walk test (6MWT), dan ejection fraction (EF) juga dinilai.Hasil: Kadar VEGF-A dan VEGFR-2 dipertahankan pada kelompok ECP, sedangkan kadar VEGF-A dan VEGFR-2 mengalami penurunan yang signifikan pada kelompok sham [ΔVEGF-A ECP vs sham: 1 (-139 to160) vs -136 (-237 to 67) pg/ml, p = 0.026; ΔVEGFR-2 ECP vs sham: -171(-844 to +1166) vs -517(-1549 to +1407) pg/ml, p = 0.021, respectively]. Kadar miR-92a meningkat secara signifikan pada kelompok ECP [5.1 (4.2 – 6.4) to 5.9 (4.8 – 6.4), p<0.001] and sham [5.2 (4.1 – 9.4) to 5.6 (4.8 – 6.3), p=0.008]. Tidak terdapat korelasi antara perubahan kadar VEGF-A, VEGFR-2, dan miR-92a [VEGF-A vs VEGFR-2 (r = 0.243, p = 0.09; uji Spearman), VEGF-A vs miR92-a (r = 0.229, p = 0.11; uji Spearman), dan VEGR-2 vs miR92-a (r = 0.08, p = 0.581; uji Spearman)].Kesimpulan: ECP mampu mempertahankan angiogenesis dengan cara mempertahankan kadar VEGF-A dan VEGFR-2. Pada kondisi iskemia, baik high shear stress (ECP) maupun low shear stress (sham) dapat menginduksi pelepasan miR-92a. ECP mempengaruhi VEGF-A, VEGFR-2, dan miR-92a secara independen.

---

Background: ECP is able to reduce angina frequency, improve quality of life, and improve exercise time-induced ischemia time. These benefits can last several years after the ECP. The mechanism for the long-term benefit of ECP has been proven by the presence of angiogenesis, which is thought to be mediated by VEGF-A, VEGFR-2, and miR-92a.

Objective: To determine the effect of ECP on VEGF-A and VEGFR-2, and its relationship with miR-92a in patients with refractory angina.

Methods: This study was a double-blind randomized clinical trial involving 50 subjects with refractory angina. Subjects were randomized (1:1) into either ECP or sham therapy groups, each administered for 1 hour, up to 35 times. Plasma VEGF-A, VEGFR-2, and miR-92a levels were measured before and after therapy using the enzyme-linked immunosorbent assay (ELISA) method for VEGF-A and VEGFR-2, as well as quantitative reverse transcription-polymerase chain reaction (qRT-PCR). ) for miR-92a. Secondary clinical outcomes such as degree of angina, quality of life, 6-minute walk test (6MWT), and ejection fraction (EF) were also assessed.

Results: VEGF-A and VEGFR-2 levels are maintained in the ECP group, while VEGF-A and VEGFR-2 levels decrease in the sham group [ΔVEGF-A ECP vs sham: 1 (-139 to160) vs -136 (-237 to 67) pg/ml, p = 0.026; VEGFR-2 ECP vs sham: -171(-844 to +1166) vs -517(-1549 to +1407) pg/ml, p = 0.021, respectively]. MiR-92a levels increase significantly in the ECP group [5.1 (4.2 – 6.4) to 5.9 (4.8 – 6.4), p<0.001] and sham [5.2 (4.1 – 9.4) to 5.6 (4.8 – 6.3), p=0.008]. There is no correlation between changes in VEGF-A, VEGFR-2, and miR-92a levels [VEGF-A vs VEGFR-2 (r = 0.243, p = 0.09; Spearman's test), VEGF-A vs miR92-a (r = 0.229 , p = 0.11; Spearman's test), and VEGR-2 vs. miR92-a (r = 0.08, p = 0.581; Spearman's test)].

Conclusion: ECP therapy is able to maintain angiogenesis by maintaining VEGF-A and VEGFR-2 levels. In ischemic conditions, both high shear stress (ECP) and low shear stress (sham) can induce the release of miR-92a. ECP affects VEGF-A, VEGFR-2, and miR-92a independently."

"Latar Belakang: Risiko perdarahan tidak berkorelasi linear dengan jumlah trombosit pada kondisi trombositopenia. Terdapat perbedaan fungsi trombosit pada trombositopenia gangguan produksi dengan destruksi perifer. Pada trombositopenia, hasil fungsi agregasi trombosit dengan light transmission aggregometry tidak valid. Diperlukan pemeriksaan fungsi trombosit yang dapat dikerjakan pada kondisi trombositopenia.Tujuan: Mengkaji fungsi agregasi trombosit pada pasien trombositopeniaMetode: Studi potong lintang terhadap 60 pasien trombositopenia gangguan produksi dan destruksi perifer di Rumah Sakit Cipto Mangunkusumo selama Desember 2023 sampai April 2024. Dilakukan pemeriksaan jumlah trombosit, IPF, dan fungsi agregasi trombosit.Hasil: Terdapat perbedaan fungsi agregasi antara trombositopenia gangguan produksi dengan destruksi perifer (40% vs 77,7%). Didapatkan perbedaan nilai IPF antara trombositopenia gangguan produksi dengan destruksi perifer (5,65% vs 21%). Tidak didapatkan korelasi antara jumlah trombosit dengan fungsi agregasi trombosit pada trombositopenia gangguan produksi maupun destruksi perifer (r=0,214, p=0,231; r=0,364 p=0,062). Tidak didapatkan korelasi antara jumlah trombosit dengan fungsi agregasi trombosit pada trombositopenia gangguan produksi maupun destruksi perifer. Didapatkan titik potong IPF 10,25% untuk membedakan trombositopenia gangguan produksi dan destruksi perifer dengan sensitivitas 80,8% dan spesifisitas 68%.Kesimpulan: Fungsi agregasi trombosit pada trombositopenia destruksi perifer lebih baik daripada trombositopenia gangguan produksi. Fungsi agregasi trombosit tidak berkorelasi dengan jumlah trombosit maupun dengan IPF.

---

Background: The risk of bleeding does not linearly correlate with platelet count in thrombocytopenia.There is difference between platelet function in central and peripheral thrombocytopenia. Platelet aggregation function assay performed by light transmission aggregometry is not valid in thrombocytopenia. Platelet aggregation assay that can be performed in thrombocytopenia is needed.

Objective: To assess platelet function in thrombocytopenia patients.

Methods: A cross-sectional study was conducted on 60 thrombocytopenic patients at Cipto Mangunkusumo Hospital from December 2023 to April 2024. Platelet count and immature platelet fraction (IPF) were done by automatic blood cell counter while platelet aggregation by Plateletworks ADP Kit

Results: There was a difference in platelet aggregation function between central thrombocytopenia and peripheral thrombocytopenia (40% vs 77.7%). A difference in IPF values was found between central thrombocytopenia and peripheral thrombocytopenia (5.65% vs. 21%). No correlation between platelet count and platelet aggregation function in thrombocytopenia (r=0.214, p=0.231 vs. r=0.364, p=0.062). No correlation was found between IPF and platelet aggregation function (r=-0.139, p=0.498 vs. r=-0.282, p=0.171). The cut-off value of IPF was 10.25% to distinguish central and peripheral thrombocytopenia.

Conclusion: Platelet aggregation function in peripheral thrombocytopenia was better than central thrombocytopenia. Platelet aggregation function did not correlate neither platelet count nor IPF."

"Latar Belakang: Derajat keparahan karsinoma hepatoselular (KHS) yang dinilai dengan klasifikasi Barcelona Clinic Liver Cancer (BCLC) merupakan faktor prognostik utama KHS. Penilaian kadar serum Vascular Endothelial Growth Factor (VEGF) dianggap dapat mencerminkan tingkat keparahan KHS. Namun, belum ada kesepakatan mengenai hubungan tingkat keparahan KHS dengan kadar serum VEGF. Tujuan : Mengetahui hubungan kadar serum VEGF dengan tingkat keparahan KHS dengan menilai perbedaan rerata kadar serum VEGF pada berbagai tingkat keparahan KHS. Metode : Penelitian ini adalah studi potong lintang untuk menentukan hubungan antara kadar serum VEGF dengan tingkat keparahan KHS berdasarkan klasifikasi BCLC. Penelitian ini dilakukan di Rumah Sakit Cipto Mangunkusumo antara bulan Januari 2015 dan Mei 2015. Uji statistik yang digunakan untuk menilai hubungan kadar serum VEGF dengan klasifikasi BCLC ialah analisis one way ANOVA, dan dilanjutkan dengan analisis post hoc Tukey Schaffe. Hasil : Sebanyak 61 subyek KHS diikutkan dalam penelitian ini. Pada penelitian ini tidak ditemukan subyek dengan BCLC stage 0. Rerata kadar serum VEGF BCLC stage A adalah 288,26±156,6 pg/ml; BCLC stage B: 434±164,8 pg/ml; BCLC stage C: 785,57±194,25 pg/ml; BCLC stage D: 1537,97±660,62 pg/ml. Analisis one way ANOVA menunjukkan perbedaan bermakna (P<0,001) antara kadar serum VEGF dengan tingkat keparahan KHS berdasarkan klasifikasi BCLC. Analisis post hoc dengan Tukey Schaffe menunjukkan adanya perbedaan bermakna antara BCLC stage A dan C (p<0,05) serta BCLC stage A dan D (p< 0.001), BCLC stage B dan D (p<0.001), dan BCLC stage C dan D (p<0.001). Tidak ditemukan perbedaan bermakna antara subyek dengan BCLC stage A dan B, dan antara BCLC stage B dan C. Kesimpulan : Didapatkan kadar serum VEGF yang meningkat sesuai dengan tingkat keparahan KHS berdasarkan klasifikasi BCLC terutama untuk BCLC stage B ke atas.

---

Background : The severity of Hepatocellular Carcinoma (HCC) stratified by Barcelona Clinic Liver Cancer (BCLC) staging classification has been one of the main prognostic factors of patients with HCC. Serum vascular endothelial growth factor (VEGF) examination can be reflect to predict the severity of HCC. Although, there is no consensus among experts about the severity of HCC staging and serum VEGF levels.

Aim : To determine the association between serum VEGF levels and severity of HCC.

Methods : A cross-sectional study to determine the association between serum VEGF levels and the severity of HCC stratified by BCLC staging classification. The study was conducted at Cipto Mangunkusumo Hospital between January 2015 and May 2015. One way ANOVA analysis was used to assess the association between serum VEGF levels and BCLC classification staging. Post hoc analysis will be done using Tukey Schaffe test.

Results: There were 61 HCC subjects included to this study. There were no subjects with BCLC stage 0. The mean VEGF serum level in patients with BCLC stage A was 288.26 ± 156.6 pg / ml; BCLC stage B: 434 ± 164.8 pg / ml; BCLC stage C: 785.57 ± 194.25 pg/ml; and BCLC stage D: 1537.97 ± 660.62 pg/ml. One way ANOVA showed significant statistical difference (P <0.001) between mean serum VEGF levels and the severity in all BCLC stages. Post hoc analysis using Tukey Schaffe test showed significant stastical difference between BCLC stage A and C (p<0.05), BCLC stage A and D (p<0.001), BCLC stage B and D (p<0.001), and BCLC stage C and D (p<0.001). There were no significant statistical differences between patients with BCLC stage A and B, and between BCLC stage B and C.

Conclusion: We found that increased levels of serum VEGF were associated with the severity of HCC based on BCLC staging classification, especially in patients with BCLC stage B and upwards."

"Tujuan : Penelitian ini bertujuan membandingkan kadar serum petanda biologik: Interleukin-6, Tumor Necrosis Factor-alpha, Matrix-Metalloproteinase-2 Dan Vascular Endothelial Growth Factor pada endometriosis stadium I-II dan stadium III-IV.Metode : Empat puluh pasien endometriosis yang terdiagnosis berdasarkan laparoskopi diambil sampel serum sebelum operasi untuk pemeriksaan petanda biologik. Pemeriksaan petanda biologik dilakukan di akhir penelitian dengan cara ELISA. Rerata dari kadar serum dilakukan uji T tidak berpasangan. Variabel yang terdapat perbedaan bermakna dilakukan pemeriksaan ROC dan ditentukan titik potong optimal.Hasil : Rerata kadar serum petanda biologik: IL-6, TNF-a, MMP-2 dan VEGF pada subjek dengan stadium endometriosis I-II dan III-IV adalah [1,39 vs 1,33] pg/ml (p>0,05); [1,5 ±0,47 vs 1,49±0,29] pg/ml (p>0,05); [152,04 ± 27,32 vs 140,98 ± 28,08] ng/ml (p>0,05) dan [238,78 vs 426,57] pg/ml (p<0,05). Perbedaan rerata VEGF memiliki nilai AUC 74,5%. Titik potong optimal VEGF ≥ 323,95 pg/ml dengan sensitivitas 71,4% dan spesifisitas 69,2%.Kesimpulan : Kadar serum IL-6, TNF-a dan MMP-2 tidak berbeda bermakna pada perempuan endometriosis stadium I-II dan stadium III-IV. Hanya kadar VEGF yang memiliki perbedaan rerata yang bermakna.

---

Purpose : The focus of this study is to compare serum biomarkers of : interleukin-6, tumor necrosis factor-alpha, matrix-metalloproteinase-2 and vascular endothelial growth factor in endometriosis stage I-II and stage III-IV.

Method : Forty endometriosis patient was diagnosed by laparoscopy. Serum sample was taken before the surgery. The serum biomarkers were analyzed with ELISA method at the end of research. Mean of serum biomarkers were tested with unpaired T test. Variable that had significant mean different was thorough ROC measurement and determined the optimal cut of point.

Result : Mean serum biomarkers level of IL-6, TNF-a, MMP-2 and VEGF of endometriosis stage I-II and stage III-IV were [1,39 vs 1,33] pg/ml (p>0,05); [1,5 ±0,47 vs 1,49±0,29] pg/ml (p>0,05); [152,04 ± 27,32 vs 140,98 ± 28,08] ng/ml (p>0,05) and [238,78 vs 426,57] pg/ml (p<0,05). Mean different of VEGF have AUC 74,5%. Optimal cut of point for VEGF ≥ 323,95 pg/ml with sensitivity 71,4% and spesificity 69,2%.

Conclusion : Mean serum level of IL-6, TNF-a and MMP-2 are not different between endometriosis stage I-II and stage III-IV. Only VEGF has significant mean different."

"ABSTRAKLatar belakang: Penyakit jantung bawaan (PJB) yang tersering adalah defek septum ventrikel (DSV), defek septrum atrium (DSA) dan duktus arteriousus paten (DAP). Keterlambatan koreksi defek dapat menyebabkan gangguan tumbuh kembang dan kualitas hidup. Tujuan: Mengetahui perbedaan status gizi dan kualitas hidup pada anak PJB asianotik sebelum dan 6 bulan-2tahun setelah koreksi dan apakah terdapat hubungan dengan jenis PJB, status gizi awal, metode dan usia koreksi.Metode: Penelitian kohort retrospektif pada 79 anak berusia 0-18 tahun dengan DSV, DSA, DAP, dan kombinasi ketiganya. Usia, jenis kelamin, jenis PJB, usia koreksi, metode koreksi, BB dan TB dinilai sebelum dan setelah koreksi.Hasil: Subyek penelitian berusia 0-15 tahun dengan mayoritas 1-5 tahun, diagnosis terbanyak adalah DSV (58,2%), dan status nutrisi awal adalah gizi kurang (50,6%). Secara keseluruhan terdapat kenaikan persentil BB/U (p<0,001), TB/U (p=0,004), dan BB/TB (p<0,001) yang bermakna sebelum dan sesudah koreksi. Tidak ada perubahan status gizi yang bermakna sebelum dan sesudah koreksi (p=0,851). Tidak ada hubungan perubahan status gizi dengan status gizi awal (p=0,451), metode koreksi (p=0,454), dan usia tindakan (p=0,861). Terdapat hubungan antara perubahan status gizi dengan ukuran defek (p=0,035). Sebanyak 29,1% memiliki gangguan kualitas hidup, 45,4% memiliki gangguan aspek emosi. Tidak ada hubungan antara gangguan kualitas hidup dengan diagnosis, metode koreksi, dan ukuran defek.Simpulan: Status gizi awal terbanyak anak dengan PJB asianotik adalah gizi kurang. Terdapat peningkatan persentil BB/U, TB/U, dan BB/TB yang bermakna 6 bulan-2 tahun setelah koreksi. Terdapat hubungan antara perubahan status gizi dengan ukuran defek. Sepertiga subyek memiliki gangguan kualitas hidup setelah koreksi. Hampir separuhnya memiliki gangguan aspek emosi.

---

ABSTRACT

Background: The most common congenital heart disease (CHD) is ventricular septal defect (DSV), atrial septal defect (ASD), and patent ductus arteriosus (DAP). Delayed correction is correlated with disturbance of growth, development and quality of life (QOL).

Aim: To determine the difference in nutritional status and QOL for acyanotic CHD before and after 6 months-2 years correction and its association with diagnosis, initial nutritional status, method and age of correction.

Method: A retrospective cohort study on 79 children aged 0-18 years old with DSV, ASD, DAP, and a combination of the 3. Age, gender, type of CHD, age and method of correction, weight and height before and after correction were evaluated.

Result: The subjects are aged 0-15 years with majority of 1-5 years, most common diagnosis is DSV (58.2%) and initial nutritional status is moderate malnutrition (50.6%). There is significant increase in weight/age (p<0.001), height/age (p=0,004) and weight/height (p<0.001) percentiles. There is no increment of nutritional status (p=0.851). There is no association between nutritional status and initial nutritional status before correction (p=0.451), method (p=0.454) and age (p=0.861) of correction. There is a statistically significant association between growth status and defect size (p=0.035). Twenty nine percent have decreased QOL, 45.4% on emotional aspect. Decreased QOL was not associated with diagnosis, method of correction and defect size.

Conclusion: The most common nutritional status in acyanotic CHD children is moderate malnutrition. There is a statistically significant increase in the percentiles 6 months-2years post correction. There is an association between changes in growth status and defect size. One third of patients have decreased QOL after correction and almost half on emotional aspect"

"Latar belakang: Immune thrombocytopenia (ITP) didiagnosis dengan mengekslusi penyebab lain trombositopenia. Mekanisme trombositopenia terjadi melalui 2 mekanisme, yaitu destruksi trombosit seperti pada pasien ITP dan penurunan produksi trombosit pada pasien leukemia. Aspirasi sumsum tulang merupakan metode yang dapat membedakan mekanisme trombositopenia yang terjadi, tetapi karena invasif tidak rutin dilakukan untuk diagnosis. Seiring dengan perkembangan zaman, dapat dilakukan pemeriksaan trombosit muda dengan teknik flouresensi untuk menilai kadar immature platelet fraction (IPF). Penelitian ini dilakukan untuk membandingkan kadar IPF pada pasien ITP dibandingkan dengan leukemia. Metode: Studi potong-lintang kadar IPF pasien anak dengan ITP dan leukemia, yang dilaksanakan dari 2017-2020 di RSUPN Cipto Mangunkusumo, Jakarta. Sampel penelitian adalah pasien anak umur kurang dari 18 tahun, yang menderita ITP dan leukemia, yang belum mendapatkan kemoterapi ataupun imunosupresan. Data penelitian diambil dari rekam medis atau pemeriksaan darah rutin. Hasil: Dari 42 pasien, didapatkan 21 pasien ITP dan 21 pasien leukemia. Terdapat perbedaan bermakna (16,6 poin) dari rerata kadar IPF pasien ITP dibandingkan pasien leukemia (P<0,001). Pasien ITP memiliki kadar rerata IPF sebesar 18,6%(SB 12,1%). Pasien leukemia memiliki kadar IPF 2%(SB 1,31%). Kesimpulan: Terdapat perbedaan bermakna kadar IPF pada pasien ITP dibandingkan pasien leukemia akut.

---

.Background and aim: Immune thrombocytopenia (ITP) is diagnosed by excluding other causes of thrombocytopenia. The thrombocytopenia itself could occur through 2 mechanisms, which were platelet destruction as in ITP, and decrease platelet production as in leukemia. Bone marrow aspiration used to be done to distinguish the mechanism of thrombocytopenia, but it has not been routinely done due to its invasiveness. Examination of young platelets with fluorescence technique are currently done to assess the level of Immature Platelet Fraction (IPF). This study was conducted to evaluate the differences in IPF levels in ITP patients compared with leukemia patients.

Methods: A cross-sectional study was carried out on the IPF levels on patients with ITP and leukemia, from 2017-2020 at Cipto Mangunkusumo General Hospital, Jakarta. The study sample was pediatric patients, less than 18 years old, diagnosed with ITP and acute leukemia, whom had not received any chemotherapy or immunosuppressants. Research data were taken from medical records and/or routine blood tests.

Results: Total of 42 patients, 21 ITP patients and 21 leukemia patients were found. There was a significant difference (16,6 poin) in the mean of IPF levels of ITP patients compared with leukemia patients (P <0.001). ITP patients had an average IPF level of 18,6% (SB 12,1). Leukemia patients have 2% IPF levels (SB 1,31).

Conclusions: There is a subtantial different in IPF in ITP patient compared to acute leukemia patients. "